Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;5(5):1527-1535.
doi: 10.3892/ol.2013.1226. Epub 2013 Mar 5.

Ki-67 and CD100 immunohistochemical expression is associated with local recurrence and poor prognosis in soft tissue sarcomas, respectively

Marcelo Campos  1 , Silvana Gisele Pegorin DE Campos, Guilherme Gomes Ribeiro, Flávia Coltri Eguchi, Sandra Regina Morini DA Silva, Cleyton Zanardo DE Oliveira, Allini Mafra DA Costa, Emílio Carlos Curcelli, Marcos Ceita Nunes, Valter Penna, Adhemar Longatto-Filho
Affiliations

Ki-67 and CD100 immunohistochemical expression is associated with local recurrence and poor prognosis in soft tissue sarcomas, respectively

Marcelo Campos et al. Oncol Lett. 2013 May.

Abstract

Soft tissue sarcomas (STSs) are a heterogeneous group of mesenchymal tumors of >50 subtypes. However, STSs represent <1% of types of cancer. Despite this low frequency, the disease is aggressive and treatment, when possible, is based on traditional chemotherapies. A number of cases of resistance to adjuvant therapies have been reported. Metastases are commonly identified in STS patients during diagnosis and the development of effective clinical parameters is crucial for correct management of the disease. The use of biological markers in cancer is a useful tool to determine patient prognosis. Ki-67 is a protein marker for proliferation of somatic cells and is widely used in prognostic studies of various types of tumor, including STSs. Cluster of differentiation 100 (CD100) is a member of the semaphorin family. The family was initially described as axon guidance molecules important for angiogenesis, organogenesis, apoptosis and neoplasia. CD100 was previously utilized as a prognostic factor in tumors and also in STSs. In the present study, protein expression of Ki-67 and CD100 was analyzed by immunohistochemistry in samples of STS patients of the Barretos Cancer Hospital (Barretos, Brazil) to establish prognostic criteria of the disease. Results demonstrate a correlation between CD100 expression and poor prognosis, consistent with a previous study. Moreover, the expression of Ki-67 was identified to correlate with presence of local or locoregional recurrence. To the best of our knowledge, no large casuistic study has revealed this correlation between Ki-67 and local recurrence in STSs. The use of Ki-67 and CD100 as markers in clinical pathological analysis may be suitable as a prognostic criterion in disease progression.

Keywords: CD100; Ki-67; poor prognosis; recurrence; soft tissue sarcomas.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Immunohistochemistry for Ki-67. (A) High grade pleomorphic undifferentiated sarcoma, (B) high grade undifferentiated sarcoma (C) metastatic sinovial sarcoma.
Figure 2
Figure 2
Immunohistochemistry for CD100. (A) High grade indiferenciated pleomorphic sarcoma, (B) leiomyosarcoma grade III, (C) sclerosant epithelioid fibrosarcoma. CD100, cluster of differentiation.
Figure 3
Figure 3
Kaplan-Meier estimate for global survival with respect to expression of CD100. CD100, cluster of differentiation.
Figure 4
Figure 4
Kaplan-Meier estimate for global survival with respect to expression of CD100. CD100, cluster of differentiation.
Figure 5
Figure 5
Kaplan-Meier estimate for locoregional recurrence free-survival with respect to expression of Ki-67.
See this image and copyright information in PMC

References

    1. Fletcher CDM, Sundaram M, Rydholm A, Coindre JM, Singer S. Soft tissue tumours: Epidemiology, clinical features, histopathological typing and grading. In: Fletcher CDM, Unni KK, Mertens F, editors. World Health Organization, International Agency for Research on Cancer. Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press; Lyon: 2002. pp. 12–18.
    1. Jones NB, Iwenofu H, Scharschmidt T, Kraybill W. Prognostic factors and staging for soft tissue sarcomas: an update. Surg Oncol Clin N Am. 2012;21:187–200. - PubMed
    1. Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S, Ladanyi M. Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer. 2011;11:541–557. - PMC - PubMed
    1. Ottaiano A, De Chiara A, Fazioli F, Talamanca AA, Mori S, Botti G, Milano A, Apice G. Biological prognostic factors in adult soft tissue sarcomas. Anticancer Res. 2005;25:4519–4526. - PubMed
    1. Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res. 2000;257:231–237. - PubMed